Observational studyEuropean journal of nuclear medicine and molecular imaging2026
Observational study in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeData on the use of fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in non-granulomatous myocarditis are limited, and no study has evaluated the diagnostic performance of combined FDG-PET and rest myocardial perfusion imaging (rMPI).
methodsWe conducted a multicenter prospective observational feasibility study of patients who underwent combined FDG-PET/CT with rMPI as well as cardiac magnetic resonance (CMR) for suspected myocarditis. When available, endomyocardial biopsy (EMB) established the diagnosis according to consensus criteria. Otherwise, the final adjudicated clinical diagnosis served as the reference standard. All patients had a minimum follow-up of 12 months following PET imaging.
resultsTwenty-five patients were included, of whom 18 (72%) were diagnosed with myocarditis. FDG-PET and rMPI demonstrated a sensitivity/specificity of 61%/100%, and 59%/71%, respectively. Inter-reader agreement for FDG-PET was excellent (κ = 0.84, 95% CI 0.62-1.00). The combination of FDG-PET and rMPI yielded a sensitivity of 82% (95% CI: 50-93%) and a specificity of 71% (95% CI: 29-96%). Late gadolinium enhancement (LGE), excluding isolated subendocardial patterns, showed a sensitivity/specificity of 72%/57%. Spatial agreement between rMPI perfusion defects and LGE on CMR was modest (κ = 0.35, 95%CI: 0.23-0.47).
conclusionCombining FDG-PET with rMPI may be a feasible imaging modality for detecting non-granulomatous myocarditis by capturing both inflammatory and fibrotic components across different disease stages.
Indexed as
Identifiers
42191946What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.